Glenmark Pharma discovers new molecule

The company has entered the oncology segment with the discovery of a new molecule.

 

New Delhi, August 25, 2014: Glenmark Pharmaceuticals has entered the oncology segment with the discovery of a new molecule. The company plans to develop and treat various types of cancers with the recent discovery.

 

Glenmark Pharmaceuticals SA, a wholly-owned unit of Glenmark, announces the discovery and initiation of studies of a novel clinical development candidate, GBR 1302, the company said in a statement.

 

GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre Located in La Chaux-de-Founds, Switzerland. It is company’s first clinical candidate targeting oncology indications.

 

The company is expecting to obtain approval for the initiation of clinical studies for the molecule during the current financial year.

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...